Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI

NCT01631266 is registered in ClinicalTrials.gov with Statens Serum Institut as lead sponsor.

NCT NCT01631266
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01631266 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI
Lead sponsor
Statens Serum Institut
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
October 31, 2014
Enrollment
979 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis